Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > RealityCheck4U here - after 3+ years as TH holder

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Apr 18, 2021 12:04pm

92 Views

Post# 33018970

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RealityCheck4U here - after 3+ years as TH holder

I have no problem with technical analysis. I don't use it, but I understand the rationale some use. Go to it, I pass no judgement. Aside from the science, it's worthwhile to understand what product is being developed and what the revenues could be -- those are super-key metrics with pharma companies. Those are the massive value drivers of biotech shares.

The one thing about technicals in regards to biotech, I understand you got this right back when it popped a few years back. Technicals served you well, very well. But biotechs can change so fast, both good and bad given the binary nature of a pipeline moving to commercialization, that it may work for a larger company or one who only has commercial products, like THTX was 2 years ago. But the share price and market cap does not look backward, it looks forward and given that any forward looking assessment is completely different in a clinical biotech, it's hard for me to understand the logic at this point in the strategic development of THTX. But to each his own. I think the financial statement implications of what they are doing is something they have never, ever seen before in their history so I'm not sure history matters as much.

Good luck with technicals though.

houbahop wrote: Thanks for the details wino.

There is some fundamentals I am pretty aware of.
As for the details of the science, I must humbly say my interest and motivations are not high enough to dig at the same level as some posters here. With all due respect to the ones taking the time to write and explain to the ignorants landing on this forum.

If you want to qualify my lack of depthness in the understanding of this specific science as ignorance, so be it. If you think I am embarrasing myself by not having the will to go pass a certain level of details, well, it is your problem.

I am interested up to a certain point to science, but I would say more importantly by the behavior of people in power in their fiduciary duties and the ones depending on them.

I prefer to base my investment decisions on technical analysis (70%) than fundamentals (30%).

I do represent another pov, not always in accordance to others. Although frustrating for some, this "other" point of view might balance the over optimism by some on this board.

So $50B market cap.? Anyone else corroborate this?